Specific cases, such as treatments targeting the ESR1 mutation in breast cancer, MSI and TMB-high in biliary tract cancer, and CDK12 mutation in head and neck cancer—detected exclusively through ctDNA but not in tissue samples—demonstrated partial responses (Fig 4C). Here, ESR1 is linked to biliary tract cancer.